

tients in whom BP developed before malignancy, at presentation and during subsequent follow-up for up to 3 years, will lead to the detection of tumours, some of which may be potentially treatable.

References

1. Lim CC, MacDonald RAH, Rook AJ. Pemphigoid eruptions in the elderly. *Trans St John's Hosp Derm Soc* 1968;4:148-52.
2. Lever WF. Pemphigus. *Medicine* 1953;32:1-123.
3. Jordan RE, Beutner EH, Witebsky E, et al. Basement zone antibodies in bullous pemphigoid. *J Am Med Assoc* 1967;200:751-8.
4. Provost TT, Tomasi TB, Jr. Evidence for complement activation via the alternative pathway in skin disease. Herpes gestationis, systemic lupus erythematosus and bullous pemphigoid. *J Clin Invest* 1973;52:1779-87.
5. Diaz LA, Rattie-H III, Saunders WS, et al. Isolation of a human epidermal cDNA corresponding to the 180 KD autoantigen recognized by bullous pemphigoid and herpes gestationis sera. Immunolocalization of this protein to the hemidesmosome. *J Clin Invest* 1990;86:1088-94.
6. Li K, Sawamura D, Giudice GJ, et al. Genomic organization of collagenous domains and chromosomal assignment of human 180-Kda bullous pemphigoid antigen-2, a novel collagen of stratified squamous epithelium. *J Biol Chem* 1991;266:24064-69.
7. Sawamura D, Nomura K, Sugita Y, et al. Bullous pemphigoid antigen (BPAG1): cDNA cloning and mapping of the gene to the short arm of human chromosome 6. *Genomics* 1990;8:722-6.
8. Liu Z, Diaz LA, Troy JL, et al. A passive transfer model of the organ-specific autoimmune disease, bullous pemphigoid, using antibodies generated against the hemidesmosomal antigen, BP180. *J Clin Invest* 1993;92:480-8.
9. Liu Z, Giudice GJ, Swartz SJ, et al. The role of complement in experimental bullous pemphigoid. *J Clin Invest* 1995;95:1539-44.
10. Rico MJ. Treatment of autoimmune blistering diseases. *Cutis* 1993;52:357-61.
11. Kolbach DN, Remme HJ, Bos MH, et al. Bullous pemphigoid successfully controlled by tetracycline and nicotinamide. *Br J Dermatol* 1995;133:88-90.
12. Venning VA, Wojnarowska F. The association of bullous pemphigoid and malignant disease: a case control study. *Br J Dermatol* 1990;123:439-45.
13. Lindelof B, Islam N, Eklund G, et al. Pemphigoid and cancer. *Arch Dermatol* 1990;126:66-8.
14. Morioka S, Sakuma M, Ogawa H. The incidence of internal malignancies in autoimmune blistering diseases: Pemphigus and bullous pemphigoid in Japan. *Dermatology* 1994;189 (suppl 1):82-4.

BEYOND EVIDENCE-BASED MEDICINE

From science to art

"The ward was full, so I put him in my room as he was moribund and screaming and I did not want to wake the ward. I examined him. He had obvious gross bilateral crepitations and a severe pleural rub. I thought the latter was the cause of the pain and screaming. I had no morphia, just aspirin, which had no effect. I felt desperate. I knew very little Russian then and there was no one in the ward who did."

"I finally instinctively sat down on the bed and took him in my arms, and the screaming stopped almost at once. He died peacefully in my arms a few hours later. It was not the pleurisy that caused the screaming, but loneliness. It was a wonderful education about the care of the dying. I was ashamed of my misdiagnosis and kept the story a secret."

Quoted from the last page of Cochrane Collaboration on evidence-based medicine

Tak-Kwan Kong

Department of Geriatrics
Princess Margaret Hospital, Hong Kong